Wall Street Zen Upgrades Humacyte (NASDAQ:HUMA) to Hold

Wall Street Zen upgraded shares of Humacyte (NASDAQ:HUMA - Free Report) from a sell rating to a hold rating in a research report released on Friday morning.

Other analysts have also issued reports about the company. D. Boral Capital reiterated a "buy" rating and set a $25.00 price objective on shares of Humacyte in a report on Monday, June 9th. HC Wainwright assumed coverage on Humacyte in a report on Wednesday, May 14th. They set a "buy" rating and a $4.00 price objective for the company. Finally, Benchmark cut their price objective on Humacyte from $17.00 to $14.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Humacyte currently has a consensus rating of "Moderate Buy" and a consensus target price of $11.71.

Humacyte Trading Down 1.4%

Shares of HUMA traded down $0.03 during trading hours on Friday, hitting $2.09. 1,436,773 shares of the company were exchanged, compared to its average volume of 3,811,612. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.28 and a current ratio of 3.68. The firm has a fifty day simple moving average of $2.06 and a 200-day simple moving average of $2.99. Humacyte has a one year low of $1.15 and a one year high of $9.79.

Humacyte (NASDAQ:HUMA - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.09. The business had revenue of $0.52 million during the quarter, compared to analysts' expectations of $0.46 million. As a group, analysts anticipate that Humacyte will post -1.27 EPS for the current fiscal year.

Insider Activity

In related news, CFO Dale A. Sander bought 20,000 shares of the business's stock in a transaction on Thursday, April 10th. The shares were bought at an average cost of $1.53 per share, for a total transaction of $30,600.00. Following the completion of the acquisition, the chief financial officer directly owned 40,600 shares in the company, valued at approximately $62,118. This represents a 97.09% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Kathleen Sebelius acquired 50,000 shares of the company's stock in a transaction dated Tuesday, April 8th. The stock was acquired at an average price of $1.32 per share, for a total transaction of $66,000.00. Following the completion of the purchase, the director directly owned 91,207 shares of the company's stock, valued at $120,393.24. This trade represents a 121.34% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 83,993 shares of company stock worth $118,224. Corporate insiders own 5.10% of the company's stock.

Hedge Funds Weigh In On Humacyte

A number of institutional investors have recently made changes to their positions in HUMA. Vanguard Group Inc. increased its stake in Humacyte by 10.8% during the fourth quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company's stock valued at $28,294,000 after acquiring an additional 543,995 shares during the period. Heights Capital Management Inc. bought a new position in Humacyte during the first quarter valued at about $6,863,000. Woodline Partners LP boosted its holdings in Humacyte by 38.7% during the first quarter. Woodline Partners LP now owns 3,950,000 shares of the company's stock valued at $6,735,000 after purchasing an additional 1,101,198 shares in the last quarter. RA Capital Management L.P. acquired a new stake in Humacyte during the first quarter valued at approximately $5,648,000. Finally, Geode Capital Management LLC boosted its holdings in Humacyte by 4.7% during the fourth quarter. Geode Capital Management LLC now owns 2,135,133 shares of the company's stock valued at $10,785,000 after purchasing an additional 94,915 shares in the last quarter. 44.71% of the stock is currently owned by institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.